Wall Street analyst Leerink believes Gilead will eventually sell courses of remdesivir for $5,000, more than the high end of the range that the drug price evaluating nonprofit Institute for Clinical and Economic Review suggested last month. Leerink estimates Gilead could sell $7.6 billion worth of the antiviral in 2022, with sales falling off thereafter. Remdesivir is the only drug to show modest improvements in COVID-19 patients. Gilead donated 1.5 million doses of it globally, and the United States received...